Abigail Brooks, MA

Decreased blood serum cholesterol levels were associated with an increased risk of plasma cell neoplasm, although there was no causal association with multiple myeloma.

Preliminary data from the SPARTAN study were presented at ASN Kidney Week 2023, demonstrating sparsentan’s impact on proteinuria and total body water over time.

Disparities in nephrology were at the forefront of multiple sessions, presentations, and conversations at ASN Kidney Week 2023.

Results called attention to a greater risk of hospitalization among patients with CKD who exhibited depressive symptoms, regardless of treatment with dialysis.

Data presented at ASN Kidney Week 2023 highlighted the patient-reported difficulty of implementing physician-recommended lifestyle changes but noted significant impacts on physical health, mental health, and overall quality of life when done successfully.

At ASN Kidney Week 2023, we collected perspectives from 10 key opinion leaders in nephrology on what they see as the most significant news in their specialty from the past year.

Results presented at ASN Kidney Week 2023 highlighted the importance of eGFR and albuminuria measurements for identifying risk of major adverse kidney disease events.

The study, presented at ASN Kidney Week 2023, sought to assess the impact of sociodemographic stress on outcomes in home dialysis among patients with ESRD.

Food insecurity was associated with more missed appointments and fluid or electrolyte-related hospitalizations among patients on hemodialysis, especially those under 55 years of age.

Findings presented at ASN Kidney Week 2023 highlighted an association between distance to the transplant center and increased clinic cancellations.

Data presented at ASN Kidney Week 2023 suggested male kidney donors recover greater kidney function than females after donation.

We sat down with Maya Clark-Cutaia, RN, MSN, PhD, assistant professor of nursing at New York University Rory Meyers College of Nursing to discuss disparities in the kidney transplantation process and how they should be addressed in future efforts.

Results presented in an abstract at ASN Kidney Week 2023 showed White patients had the greatest access to waitlisting and transplantation.

We sat down with Amit Garg, MD, PhD, to discuss results from the EnAKT LKD trial and the development of a multicomponent intervention model for increasing access to kidney transplantation

Oliver Gross, MD, discusses the unmet need in Alport Syndrome and the implications of study results presented at ASN Kidney Week 2023.

EnAKT LKD was conducted across 26 CKD programs in Ontario Canada, offering a multi-component intervention designed to target several barriers thought to prevent kidney transplantation and living donation - however, results showed no significant difference between the intervention and usual care groups.

Primary results presented at ASN Kidney Week 2023 showed spironolactone missed the trial's primary endpoint.

Aldosterone synthase inhibition dose-dependently reduced albuminuria by up to 40% in participants with CKD, according to study results presented at ASN Kidney Week 2023.

Data presented at ASN Kidney Week 2023 described the effects of SGLT2 inhibition in young patients with Alport syndrome.

Results presented at ASN Kidney Week 2023 highlighted the efficacy of twice weekly hemodialysis.

A subgroup analysis of hemodialysis patients treated with cognitive behavioral therapy for insomnia was presented at ASN Kidney Week 2023.

Our gastroenterology month in review highlights multiple FDA approvals, conference coverage from ACG 2023, and other top news in gastroenterology.

Patients with progressive DKD had greater gastrointestinal symptom scores than those with stable DKD.

Our October 2023 hepatology month in review features phase 2/3 data, updates in the hepatology pipeline, and other top news.

Marla Dubinsky, MD, discusses findings from the LUCENT program and their role in the recent FDA approval of mirikizumab for ulcerative colitis.

Results from both phase 2 trials were presented in poster abstracts at ACG 2023.

Atrasentan demonstrated superiority versus placebo for reduction in proteinuria through 36 weeks.

In this interview, Remo Panaccione, MD, discusses results from the long-term extension of the GALAXI phase 2 study for guselkumab in Crohn disease and their implications in clinical practice.

Findings were presented in an abstract at ACG 2023, highlighting the importance of addressing bowel urgency in patients with ulcerative colitis.

Results showed higher-exposure dupilumab met the study’s primary endpoint for peak esophageal intraepithelial count ≤6 eos/high-power field.